New Hep C Treatment Being Tested
REHOVOT, Israel - U.S. health officials estimate that more Americans will die during this decade of hepatitis C (HCV) infection than AIDS.
Officials at XTL Biopharmaceuticals Ltd. are trying to make a difference in these statistics. After successfully passing Phase IA clinical trails earlier this year with their drug XTL-002, researchers have announced the commencement of a Phase IB clinic study. The drug is a fully human, high-affinity monoclonal antibody that has reduced the viral levels of HCV virus.
The World Health Organization (WHO) estimates some 170 million people worldwide suffer from chronic HCV. There are 4 million carriers of the virus in the United States alone.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
The Importance of Hand Hygiene in Clostridioides difficile Reduction
November 18th 2024Clostridioides difficile infections burden US healthcare. Electronic Hand Hygiene Monitoring (EHHMS) systems remind for soap and water. This study evaluates EHHMS effectiveness by comparing C difficile cases in 10 hospitals with CMS data, linking EHHMS use to reduced cases.
